Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ViroPharma Incorporated
Exton, Pennsylvania, United Statesviropharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ViroPharma was a commercial-stage biopharmaceutical company specializing in rare diseases. Its lead product, Cinryze—a C1 esterase inhibitor for hereditary angioedema—was approved and generating significant revenue at the time of its acquisition. The company also marketed Vancocin for severe bacterial infections[5][8]. Clinical results for Cinryze demonstrated significant reduction in severity, duration, and frequency of HAE attacks[5].
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Small moleculesProtein/Enzyme replacement therapies (notably C1 esterase inhibitor)
- Industry
- Biotech
02
Partnerships
No major external partnerships highlighted immediately prior to or during the acquisition period.
Beyond the preview
Go deeper on ViroPharma Incorporated.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViroPharma Incorporated.